Update on radionuclide therapy in oncology

Cornelia Nitipir^{1

2}, Dana Niculae³, Cristina Orlov¹, Maria Alexandra Barbu¹, Bogdan Popescu¹, Ana Maria Popa¹, Anca Mihaela Stoian Pantea², Adina Elena Stanciu⁴, Bianca Galateanu⁵, Octav Ginghina⁶, Georgios Z Papadakis⁷, Boris N Izotov⁸, Demetrios A Spandidos⁹, Aristides M Tsatsakis¹⁰, Carolina Negrei¹¹

Affiliations

¹ Oncology Department, Elias University Emergency Hospital, 'Carol Davila' University of Medicine and Pharmacy, 011461 Bucharest, Romania.
² Hygiene Department, 'Carol Davila' University of Medicine and Pharmacy, 050463 Bucharest, Romania.
³ Radiopharmaceuticals Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering, 077125 Magurele, Romania.
⁴ Department of Carcinogenesis and Molecular Biology, Institute of Oncology, 022328 Bucharest, Romania.
⁵ Department of Biochemistry and Molecular Biology, University of Bucharest, 050095 Bucharest, Romania.
⁶ Department of Surgery, Faculty of Dental Medicine, 'Sf. Ioan' Clinical Emergency Hospital, 'Carol Davila' University of Medicine and Pharmacy, 042122 Bucharest, Romania.
⁷ Foundation for Research and Technology Hellas (FORTH), Institute of Computer Science (ICS), Computational Biomedicine Laboratory (CBML), 71003 Heraklion, Greece.
⁸ Department of Analytical Toxicology, Pharmaceutical Chemistry and Pharmacognosy, Sechenov University, 119991 Moscow, Russia.
⁹ Laboratory of Clinical Virology, University of Crete Medical School, 71003 Heraklion, Greece.
¹⁰ Department of Toxicology and Forensic Sciences, University of Crete Medical School, 71003 Heraklion, Greece.
¹¹ Departament of Toxicology, Faculty of Pharmacy, 'Carol Davila' University of Medicine and Pharmacy, 020956 Bucharest, Romania.

PMID: 29344129
PMCID: PMC5754838
DOI: 10.3892/ol.2017.7141

Update on radionuclide therapy in oncology

Cornelia Nitipir et al. Oncol Lett. 2017 Dec.

. 2017 Dec;14(6):7011-7015.

doi: 10.3892/ol.2017.7141. Epub 2017 Oct 5.

Authors

Affiliations

¹ Oncology Department, Elias University Emergency Hospital, 'Carol Davila' University of Medicine and Pharmacy, 011461 Bucharest, Romania.
² Hygiene Department, 'Carol Davila' University of Medicine and Pharmacy, 050463 Bucharest, Romania.
³ Radiopharmaceuticals Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering, 077125 Magurele, Romania.
⁴ Department of Carcinogenesis and Molecular Biology, Institute of Oncology, 022328 Bucharest, Romania.
⁵ Department of Biochemistry and Molecular Biology, University of Bucharest, 050095 Bucharest, Romania.
⁶ Department of Surgery, Faculty of Dental Medicine, 'Sf. Ioan' Clinical Emergency Hospital, 'Carol Davila' University of Medicine and Pharmacy, 042122 Bucharest, Romania.
⁷ Foundation for Research and Technology Hellas (FORTH), Institute of Computer Science (ICS), Computational Biomedicine Laboratory (CBML), 71003 Heraklion, Greece.
⁸ Department of Analytical Toxicology, Pharmaceutical Chemistry and Pharmacognosy, Sechenov University, 119991 Moscow, Russia.
⁹ Laboratory of Clinical Virology, University of Crete Medical School, 71003 Heraklion, Greece.
¹⁰ Department of Toxicology and Forensic Sciences, University of Crete Medical School, 71003 Heraklion, Greece.
¹¹ Departament of Toxicology, Faculty of Pharmacy, 'Carol Davila' University of Medicine and Pharmacy, 020956 Bucharest, Romania.

PMID: 29344129
PMCID: PMC5754838
DOI: 10.3892/ol.2017.7141

Abstract

Unstable isotopes and their capacity to emit ionizing radiation have been employed in clinical practice not only for diagnostic, but also for therapeutic purposes, with significant contribution in several fields of medicine and primarily in the management of oncologic patients. Their efficacy is associated with their ability to provide the targeted delivery of ionizing radiation for a determined duration. These compounds can be used for curative or palliative treatment, as well as for a diagnostic-therapeutic (theranostic) approach. This review summarises the most recent trends in radionuclide treatment for several malignancies, including prostate cancer, neuroendocrine tumours, and hematological and thyroid malignancies, in which radionuclide-based therapies have been employed with high effectiveness.

Keywords: iodine; lutetium; particle; radionuclide; yttrium; β-emitting.

PubMed Disclaimer